REPL Stock Price
Replimune Group, Inc.
REPL stock price is $11.39 (-5.95% on the day), giving Replimune Group, Inc. a market cap of $1.07B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
REPL Stock Overview
- Price
- $11.39
- Previous close
- $12.11
- Open
- $12.05
- Market cap
- $1.07B
- P/E ratio
- -3.4
- 52-week range
- $1.50 - $16.33
- 1-year price target
- $19.50
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 40
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | REPL | $11.39 | -5.9% | 1.86M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |